Valuation dashboard for Baxter International Inc. (BAX) with P/E N/A, P/B 1.93, EV/EBITDA 24.1 and dividend yield 0.17%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution.
Analysis Summary
Baxter International Inc. reported revenue of $11.24B in the most recent fiscal year, growing at a 5-year CAGR of -0.7%.
Trailing-twelve-month margins: gross margin 30.1%, operating margin -1.9%, net margin -6.2%.
At $25.49 (closing price, November 3, 2026), BAX has negative trailing earnings (P/E not meaningful) and an ROE of -11.62%. Market capitalisation stands at $13.2B, placing it among large-cap names.
Balance sheet quality for BAX: debt-to-equity ratio of 1.35, current ratio of 1.79 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.93 |
| EV / EBITDA | 24.1 |
| Dividend Yield | 0.17% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BAX | Baxter International Inc. | $13.2B | 1.93 | -11.6% | |
| ICUI | ICU Medical, Inc. | $4.0B | 137.14 | 1.89 | 1.4% |
| FMS | Fresenius Medical Care AG & Co. KGaA | $12.0B | 11.76 | 0.83 | 7.2% |
| DVA | DaVita Inc. | $11.5B | 14.30 | -133.2% | |
| ISRG | Intuitive Surgical, Inc. | $155.7B | 52.91 | 9.62 | 17.0% |
| 0R29.L | Intuitive Surgical, Inc. | $150.3B | 54.04 | 9.87 | 17.0% |
| 0R19.L | Becton, Dickinson and Company | $54.2B | 59.91 | 2.24 | 3.8% |
| BDX | Becton, Dickinson and Company | $54.0B | 59.69 | 2.23 | 3.8% |
Price
| Price | $25.49 (closing price, November 3, 2026) |
| Market Cap | $13.2B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | -11.62% |
| Return on Invested Capital | -1.34% |
| Return on Assets | -3.72% |
| Gross Margin | 30.09% |
| Operating Margin | -1.90% |
| Net Margin | -6.23% |
Related companies: ICUI · FMS · DVA · ISRG · 0R29.L · 0R19.L · BDX · 0KW4.L
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of BAX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks